Daniel Wang, MD

Daniel Wang, MD, is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center.

Articles by Daniel Wang, MD

As RP1 Heads to Melanoma Clinics, Experts Look to Streamline Rollout and Rethink Response Criteria

ByJonah Feldman,Vincent Ma, MD,Michael K. K. Wong, MD, PhD,Daniel Wang, MD,David Savage, MD, PhD

August 18th 2026

Following the FDA approval of vusolimogene oderparepvec plus nivolumab, melanoma specialists are preparing for real-world clinical use while rethinking how to design future intratumoral therapy trials.

Decisions on How to Treat Progressive Desmoid Tumors

ByDaniel Wang, MD,Mark Agulnik, MD

May 27th 2026

Mark Agulnik, MD, and Daniel Wang, MD, discuss risk assessment and treatment approaches with systemic therapy for desmoid tumors.

Latest Updated Articles

As RP1 Heads to Melanoma Clinics, Experts Look to Streamline Rollout and Rethink Response Criteria
August 18th 2026

Daniel Wang, MD

Articles by Daniel Wang, MD

As RP1 Heads to Melanoma Clinics, Experts Look to Streamline Rollout and Rethink Response Criteria

Decisions on How to Treat Progressive Desmoid Tumors

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Behind the FDA Approval: Daraxonrasib Delivers in Pancreatic Cancer

FDA Grants Fast Track Designation to ADC Varseta-M for mCRC

White Blood Cell Count May Help Refine Risk Assessment in Polycythemia Vera

Strategies Shift Beyond Traditional Management of Immune Thrombocytopenia

FDA Clears IND for ADI-212, a PSMA-Targeted CAR T, in mCRPC